Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
Mahmud Mahamid1,3, Reuven Mader4, Rifaat Safadi1,2 1Liver Unit, Holy Family Hospital, Nazareth, Israel; 2Hadassah Medical Center, Jerusalem, Israel; 3Shaare Zedek Medical Center, Jerusalem, Israel; 4Rheumatology Unit, Ha’emek Medical Center, Afula, Israel Background: Elevation of liver...
Guardado en:
Autores principales: | Mahamid M, Mader R, Safadi R |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2ff58f96397e4eb1b71e8d44f2d418f2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
por: Cutolo M, et al.
Publicado: (2013) -
The effect of disease activity on body composition and resting energy expenditure in patients with rheumatoid arthritis
por: Binymin K, et al.
Publicado: (2011) -
Targeted therapy of rheumatoid arthritis via macrophage repolarization
por: Xu Zhou, et al.
Publicado: (2021) -
A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis
por: Ishii N, et al.
Publicado: (2021) -
Regulating Gut Microbiome: Therapeutic Strategy for Rheumatoid Arthritis During Pregnancy and Lactation
por: Yao Yao, et al.
Publicado: (2020)